Afatinib, ceritinib, gefitinib and osimertinib were purchased from Selleck Chemicals. Carboplatin, cisplatin, docetaxel and paclitaxel were purchased from Sigma-Aldrich; Merck KGaA. Pemetrexed was purchased from Toronto Research Chemicals (37 (link),38 (link)). A549 and A549/KL-1 cells (2,000 cells/well) were seeded into 96-well plates, and the drugs were added in increasing concentrations (0, 0.01, 0.1, 1, 10 and 100 µM) at room temperature. The half maximal inhibitory concentration (IC50) value was defined as the concentration of an anticancer agent required to reduce growth by 50%. The corrected absorbance of each sample compared with that of the untreated control was calculated by MTT assay using the absorbance wavelength at 570 nm.
Protocol detail
Anti-Cancer Drug Cytotoxicity Assay
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
A549 cells
Afatinib
Anticancer agent
Assay
Carboplatin
Cells
Ceritinib
Cisplatin
Docetaxel
Drugs
Gefitinib
Inhibitory
Osimertinib
Paclitaxel
Corresponding Organization :
Other organizations : Nippon Medical School
Top 5 similar protocols
Variable analysis
independent variables
- Afatinib
- Ceritinib
- Gefitinib
- Osimertinib
- Carboplatin
- Cisplatin
- Docetaxel
- Paclitaxel
- Pemetrexed
- Half maximal inhibitory concentration (IC50) value
- Corrected absorbance of each sample compared with that of the untreated control
- A549 and A549/KL-1 cells (2,000 cells/well) were seeded into 96-well plates
- Drugs were added in increasing concentrations (0, 0.01, 0.1, 1, 10 and 100 µM) at room temperature
- MTT assay using the absorbance wavelength at 570 nm
- Untreated control
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!